Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) was downgraded by stock analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report released on Tuesday.
A number of other analysts have also issued reports on the company. Needham & Company LLC reissued a “hold” rating on shares of Collegium Pharmaceutical in a research note on Friday, August 9th. Piper Sandler restated a “neutral” rating and issued a $37.00 target price (down from $39.00) on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Jefferies Financial Group raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and upped their price target for the stock from $41.00 to $44.00 in a research report on Friday, June 7th. Truist Financial lifted their price target on shares of Collegium Pharmaceutical from $40.00 to $42.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, HC Wainwright upgraded Collegium Pharmaceutical from a “neutral” rating to a “buy” rating and set a $47.00 price objective for the company in a report on Tuesday, July 30th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.
Collegium Pharmaceutical Trading Up 0.3 %
Shares of NASDAQ:COLL traded up $0.12 during trading on Tuesday, reaching $36.21. The stock had a trading volume of 435,975 shares, compared to its average volume of 467,205. The company has a quick ratio of 1.14, a current ratio of 1.21 and a debt-to-equity ratio of 1.98. The stock has a market cap of $1.18 billion, a P/E ratio of 15.04 and a beta of 0.93. The business has a fifty day moving average price of $33.50 and a 200-day moving average price of $34.94. Collegium Pharmaceutical has a fifty-two week low of $20.95 and a fifty-two week high of $40.95.
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. The company had revenue of $145.28 million during the quarter, compared to the consensus estimate of $143.94 million. During the same period in the previous year, the firm posted $1.13 EPS. Collegium Pharmaceutical’s revenue was up 7.2% on a year-over-year basis. As a group, analysts anticipate that Collegium Pharmaceutical will post 5.73 earnings per share for the current fiscal year.
Insider Transactions at Collegium Pharmaceutical
In related news, EVP Scott Dreyer sold 56,807 shares of Collegium Pharmaceutical stock in a transaction on Friday, May 24th. The shares were sold at an average price of $33.98, for a total transaction of $1,930,301.86. Following the transaction, the executive vice president now owns 105,902 shares in the company, valued at approximately $3,598,549.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, CFO Colleen Tupper sold 19,710 shares of Collegium Pharmaceutical stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $34.21, for a total transaction of $674,279.10. Following the sale, the chief financial officer now owns 130,845 shares in the company, valued at $4,476,207.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Scott Dreyer sold 56,807 shares of the company’s stock in a transaction on Friday, May 24th. The shares were sold at an average price of $33.98, for a total transaction of $1,930,301.86. Following the completion of the transaction, the executive vice president now owns 105,902 shares of the company’s stock, valued at $3,598,549.96. The disclosure for this sale can be found here. Company insiders own 3.98% of the company’s stock.
Institutional Investors Weigh In On Collegium Pharmaceutical
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. ProShare Advisors LLC increased its position in shares of Collegium Pharmaceutical by 3.3% during the first quarter. ProShare Advisors LLC now owns 8,826 shares of the specialty pharmaceutical company’s stock worth $343,000 after acquiring an additional 281 shares during the last quarter. Louisiana State Employees Retirement System raised its stake in shares of Collegium Pharmaceutical by 1.9% in the 2nd quarter. Louisiana State Employees Retirement System now owns 16,500 shares of the specialty pharmaceutical company’s stock valued at $531,000 after purchasing an additional 300 shares in the last quarter. SummerHaven Investment Management LLC lifted its position in shares of Collegium Pharmaceutical by 1.1% during the fourth quarter. SummerHaven Investment Management LLC now owns 34,034 shares of the specialty pharmaceutical company’s stock worth $1,048,000 after purchasing an additional 368 shares during the last quarter. Texas Permanent School Fund Corp lifted its position in shares of Collegium Pharmaceutical by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 28,541 shares of the specialty pharmaceutical company’s stock worth $1,108,000 after purchasing an additional 369 shares during the last quarter. Finally, Illinois Municipal Retirement Fund grew its stake in Collegium Pharmaceutical by 2.1% in the fourth quarter. Illinois Municipal Retirement Fund now owns 19,879 shares of the specialty pharmaceutical company’s stock worth $612,000 after purchasing an additional 411 shares in the last quarter.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.